Kerry Casey is a Director of Preclinical and Translational Research in Immunology and Inflammation at Regeneron, where she has spent over six years advancing the company's immunology pipeline from early discovery through clinical translation. Her current work focuses on shaping asset strategy by mapping innate and adaptive immune responses across tissue microenvironments and species — a biological lens she has refined across more than 15 years in the field.

Kerry's career in industry began at MedImmune, where she spent nearly eight years as a Program Lead and Systems Immunology Group Lead supporting IND-enabling packages for a broad rheumatic disease portfolio spanning IL-21, CD40L, Type I IFN, and B cell depletion programs, among others. From there she held scientific leadership roles at the Allen Institute for Immunology and Bristol Myers Squibb, where she led early-to-late preclinical development for an immuno-oncology small molecule portfolio, before joining Regeneron in 2019. At Regeneron she has led clinical biomarker strategy for costimulatory bispecifics and IL-2RG pathway programs, rising through associate director to her current role as director. Alongside her industry career, she served as Affiliate Faculty in the School of Systems Biology at George Mason University for six years, contributing to research on type I interferon activity in lupus and organ-specific inflammation.

Kerry's scientific foundation was built during her postdoctoral fellowship at the University of Minnesota, where her work on CD8 T cell migration and memory retention contributed to launching the field of tissue-resident memory — among the most consequential areas of modern immunology. She brings that foundational curiosity to every stage of drug development, driven by the goal of understanding the pathways underlying human disease and delivering the science that brings new medicines to patients.